• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    G

    Gujarat Cancer Research Institute

    cancerindia.org
    399论文总数
    4,481引用总数

    Gujarat Cancer & Research Institute (GCRI) is a state owned cancer research institute in Gujarat, India. It was established in 1972. It is one of the 25 government funded Regional Cancer Centres in India.

    论文量&引用量时间轴

    机构学者

    论文(399)

    年份
    起
    –
    止
    排序
    1Gut Microbiome Modulates Carcinogenesis, Immunotherapy Efficacy and Treatment Resistance
    Goutham Sunny, Abinash Patnaik, Rajan Yadav

    The gut microbiome (GM) has emerged as a significant determinant of cancer biology, which influences carcinogenesis, therapeutic efficacy and toxicity associated with treatment. Dysbiosis contributes to the initiation and progress of tumors due to long-term inflammatory reaction, generation of genotoxins, and immune system evasion in tumors such as colorectal, gastric, pancreatic, hepatic cancers, and prostate tumors. Microbial diversity and the growth of specific taxa that include Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila, and others have been positively correlated with efficacy of immune checkpoint inhibitors (ICIs) in the GM. These effects are mediated by microbial metabolites, namely, short-chain fatty acids and menaquinone (vitamin K2) through immunomodulation and toxicity control. Conversely, bacterial dysbiosis and pathological taxa induced by antibiotics complicate the cure of infection and lead to immune-related adverse events (irAEs). Future interventions such as transplantation of fecal microbiota, next-generation probiotics and engineered biotherapeutics have the potential to restore the ICI responsiveness and decrease the toxicity. To implement microbiome-based biomarkers and therapeutics in precision oncology, the existing issues of standardization, causality, and clinical translation should be solved. The GM represents a new frontier in cancer treatment, combining immunology, metabolism and microbial ecology to further the personalized medicine. This narrative review synthesizes molecular and clinical findings regarding the influence of the GM on carcinogenesis, immunotherapy efficacy, resistance, and toxicity, while also delineating translational initiatives for the integration of microbiome-based biomarkers and therapies into precision oncology.

    2026Discover Medicine(2026)引用:40
    引用
    AI阅读
    加入学术空间
    2Impact of Thrombocytopenia on Bleeding and Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention with Dual-Antiplatelet Therapy
    Vishnu Sharma, Rajat Pachori, Vansh Bagrodia, Abhinav Agarwal, Arpita Digwal, Yajat Raisinghani, Naman Modi, Vansh Gupta, Toshit Vijayvergia, Abhishek Jhajharia, Harshvarshan Sharma, Prinshu Garg,

    Abstract Background Patients with thrombocytopenia undergoing percutaneous coronary intervention (PCI) are at an elevated risk of bleeding and adverse cardiovascular events due to dual-antiplatelet therapy (DAPT). Limited data exist on the safety of DAPT in this subset of patients. Methods This single-centre prospective cohort study was conducted at SMS Medical College, Jaipur, India, over 12 months (March 2024–March 2025). A total of 368 patients with baseline (pre-PCI) thrombocytopenia who underwent elective or emergency PCI while on DAPT were enrolled. DAPT comprised aspirin plus a P2Y12 inhibitor: clopidogrel in 317 patients (86.1%), ticagrelor in 48 (13.0%), and prasugrel in 3 (0.8%), with the choice based on clinician discretion; the distribution did not differ significantly across thrombocytopenia grades (p = 0.204). DAPT was generally maintained for 6–12 months per institutional protocol, without a standardized de-escalation strategy. Thrombocytopenia was classified based on pre-procedural platelet counts as mild (100,000–150,000/mm³; n = 237, 64.4%), moderate (50,000–100,000/mm³; n = 104, 28.2%), or severe (30,000–50,000/mm³; n = 27, 7.3%). The primary outcomes were major adverse cardiovascular events (MACE), defined as a composite of total death, myocardial infarction (MI), coronary revascularization, stroke, and hospitalization due to heart failure; and bleeding events assessed using Bleeding Academic Research Consortium (BARC) criteria. Secondary outcomes included in-hospital mortality, stent thrombosis, target vessel revascularization, and post-PCI MI. Follow-up was conducted at 1, 2, and 6 months post-PCI. Multivariate logistic regression was used to adjust for confounders across three sequential models (demographics; clinical variables; procedural outcomes). Results Severe thrombocytopenia independently predicted higher risks for MACE (HR: 2.30, CI: 1.89–2.81) and bleeding (HR: 2.88, CI: 2.37–3.49) across all models. Mild thrombocytopenia showed no significant risk after adjustment for confounders. Patients with moderate thrombocytopenia demonstrated consistent risks for both outcomes. Smoking and history of PCI/MI significantly correlated with thrombocytopenia severity (p < 0.01). Conclusion Moderate and severe thrombocytopenia are independently associated with increased risks of bleeding and cardiovascular events in patients on DAPT post-PCI. These observational findings support the incorporation of thrombocytopenia severity into existing risk stratification frameworks; however, as this study did not evaluate alternative management strategies, prospective randomized trials are needed to determine whether modified antiplatelet regimens can improve outcomes in this high-risk population.

    2026The Egyptian Heart Journal(2026)引用:24
    引用
    AI阅读
    加入学术空间
    3ASO Visual Abstract: MORPHology and Inter-Observer Variation in Peritoneal Disease Assessment among Expert Peritoneal Malignancy SUrgeonS—The MORPHEUS Study
    Aditi Bhatt, Vivekanand Sharma,Ajinkya Pawar,Mohammad Alyami, Brian Badgwell,Lana Bijelic, Cecile Brigand, Pedro Cascales, Peter Cashin,Tom Cecil, Haroon M. Choudry,Marcello Deraco,

    Background The Peritoneal Cancer Index recorded at laparotomy is based on visual and palpable inspection of peritoneal surfaces for disease. This study aimed to analyze interobserver variation in assigning the lesion score (LS) and morphologic term (MT) to characterize peritoneal lesions (PL) and predict the probability of malignancy (POM) among surgeons with expertise in cytoreductive surgery (CRS) for peritoneal malignancies. Methods The study selected 80 intraoperative images of PLs depicting different morphologic appearances of PLs arising from different primary tumors in various peritoneal regions. In the study, 50 expert peritoneal malignancy surgeons were asked to assign an LS to the region in question, select the MT or MTs to describe the PL, and predict the POM. Information on the presence of disease on histopathology was not provided at this point. Inter-observer reliability was evaluated using Krippendorff's alpha (alpha). A consensus was reached if any option received more than 75% of the votes. Results The study participants comprised 41 (82%) of 50 experts. Consensus on LS was achieved for 18 images (22.5%), with low agreement (alpha = 0.174). For MTs, a consensus was reached for 21 images (26.5%; alpha = 0.0902, denoting low and unreliable agreement. Of these 21 images, the MT used was "tumor nodule" for 90.4% of the images (p < 0.001). The POM was accurately predicted in 52.5% of the cases (alpha = 0.155). Administration of neoadjuvant chemotherapy had no impact on the surgeons' assessment of the three parameters. Conclusions Even the most experienced CRS surgeons showed high interobserver variation and unreliable agreement in the description and accurate characterization of PLs on pictorial records. A Delphi consensus to standardize the MT used and scoring of PL could reduce discordance.

    2026Annals of Surgical Oncology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Primary Malignant Glandular Tumor of the Vulva: A Three-Case Series and Review of Literature.
    Varnika Rai,Anurag Saha,Shailee Mehta, Aishwarya Toshniwal,Priti Trivedi

    ABSTRACT:Vulvar cancer has an incidence of 2-3 per 100,000 women and accounts for 5% of all female genital tract (FGT) malignancies. About 90% of them are squamous cell carcinoma (SCC). Primary malignant glandular tumors of the vulva (PMGTV) are rare, diverse tumors with different prognoses and differentials. We present three cases of PMGTV diagnosed at our institution over 11 years (2013-2023) in the present study. Hospital intranet and medical records provided required clinical, histopathology, and immunohistochemistry (IHC) data. There were only three reported cases of PMGTV. The most common presentation was a painful mass growing rapidly. Most of the tumors were high-grade, and IHC was required for a definite diagnosis. A spectrum of variable entities was diagnosed, namely, adenoid cystic carcinoma (ADC), adenocarcinoma intestinal type, and adenocarcinoma of mammary gland type (AMGT). PMGTVs are rare entities and resemble morphologically and immunophenotypically tumors of other systemic sites, making exclusion of any primary malignancy mandatory. A large panel of immunohistochemistry is needed to typify them. Due to the rarity of the disease, no definite treatment guidelines are present.

    2026Indian journal of pathology & microbiology(2026)
    引用
    AI阅读
    加入学术空间
    5Uterine Sarcoma: A 10-Year Retrospective Analysis of Clinicopathological and Prognostic Factors of Surgically Treated Cases
    Japhia David,Ruchi Arora, Abhilash Vasanth, Kaustubh Burde, Bijal Patel,Chetana Parekh

    Background: This study aims to analyse the clinicopathological features of uterine sarcoma (US) and its impact on the survival outcomes. Methods: This is a retrospective observational study including 85 patients of histologically proven US, surgically treated during the period of January 2010 to December 2019. The patients were staged according to the FIGO staging system. Surgery was the mainstay of management with adjuvant treatment administered based on the stage and histopathological subtype. Descriptive analysis of the sociodemographic and clinicopathological features was done and survival analysis was done using Kaplan-Meier method. Results: The mean age of presentation in our study was 50.8 years for uterine leiomyosarcoma (ULMS), 45.5 years for low grade endometrial stromal sarcoma (LGESS), 48.1 years for high grade endometrial stromal sarcoma (HGESS) and 49.6 years in the OTHERS group. The majority were diagnosed in stage I (ULMS = 37.6%, LGESS = 16.5%, HGESS = 4.7%; OTHERS = 4.7%). The overall recurrence rate was 56.5%. 5-year overall survival (OS) and disease-free survival (DFS) rate of adenosarcoma (AS) was 100%, respectively. LGESS showed a 5-year OS and DFS rate of 86.3% and 60.5%, respectively. The 5-year OS and DFS rate of ULMS was calculated to be 77.7% and 39.9%, respectively. The 3-year OS and DFS of HGESS has been calculated to be 58.3% and 22.2%, respectively. Significance of serum lactate dehydrogenase value, stage of the tumour and the nature of adjuvant treatment were demonstrated for recurrence. Conclusion: US tend to recur. However, AS and LGESS show better survival outcomes as per our study. A proper workup with intervention including appropriate adjuvant treatment would help to mitigate the severity of the disease.

    2026Ecancermedicalscience(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 399 篇论文

    合作机构(100)

    All India Institute of Medical Sciences合作论文 6
    塔塔纪念医院合作论文 5
    Gujarat University合作论文 5
    Fondazione IRCCS Istituto Nazionale dei Tumori,Istituti di Ricovero e Cura a Carattere Scientifico合作论文 4
    Indira Gandhi Medical College合作论文 3
    Command Hospital合作论文 3
    霍米巴巴国家研究所合作论文 3
    Gujarat Cancer & Research Institute合作论文 3
    卢旺天主教大学合作论文 3
    Maharaja Sayajirao University of Baroda合作论文 3

    机构统计